Patients with persistent upper-back itch from notalgia paresthetica may get some relief with oral difelikefalin (Korsuva), phase 2 data from a randomized, double-blinded placebo-controlled trial ...
Notalgia paresthetica, a neuropathic disorder characterized by recurrent itching in the upper back, is resistant to many treatments. Oral difelikefalin is being studied as a potential therapy. New ...
STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia ...
STAMFORD, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics (CARA), Inc. , a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback